-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Promoting the transformation of innovative achievements, HealthGen's important subsidiary receives invention patent certificate
Published Time:
2023-05-12
On the evening of May 10, Jiankangyuan (600380.SH) announced that its important subsidiary, Lizhu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Lizhu Group"), received an Invention Patent Certificate from the State Intellectual Property Office.
This invention patent involves enteric microspheres, their preparation methods and formulations, and their uses. It is understood that the enteric microspheres include, from the inside out, a drug core, a first isolation layer, a second isolation layer, and an enteric layer, with the drug core containing rabeprazole and /or pharmaceutically acceptable salts of rabeprazole and the first excipient.
According to the announcement, this patented technology has been applied to Lizhu Group's rabeprazole microsphere enteric-coated tablet R&D project. The rabeprazole microsphere enteric-coated tablet 2022 was approved for clinical trials in the year. The approved clinical trial indications for this drug are : 1. Treatment of duodenal ulcers and gastroesophageal reflux disease; 2. Treatment of children (12-1 7 years old ) duodenal ulcers and gastroesophageal reflux disease; 3. Treatment of non-erosive gastroesophageal reflux disease; 4. Treatment of gastric ulcers; 5. Eradication of Helicobacter pylori; 6. Prevention of gastric ulcers caused by nonsteroidal anti-inflammatory drugs. It is introduced that this drug uses a multi-unit drug delivery system, which can rapidly disintegrate and distribute evenly in the body, providing rapid onset of action without the risk of sudden release, suitable for children, the elderly and other populations requiring low-dose medication.
Currently, the proton pump inhibitors on the market in China include omeprazole, rabeprazole and six other formulations. 。 According to IQVIA's sample statistical estimation data, the domestic terminal sales of oral proton pump inhibitors in 2021 were approximately RMB 7.718 billion. According to the CDE review center website, the R&D progress of Lizhu Group's rabeprazole microsphere enteric-coated tablets is at the forefront of the industry.
It is reported that Lizhu Group has made early arrangements for rabeprazole. According to data from MiNet, rabeprazole is an innovative drug and exclusive product approved by Lizhu Group in 2007 year, and has maintained rapid growth in China's public medical institutions in recent years.
The acquisition and application of this invention patent will help Jiankangyuan further improve its intellectual property protection system, fully leverage its independent intellectual property advantages, and enhance its core competitiveness. With the successive approval of new indications and new dosage forms, the sales of this product are expected to continue to rise, leading the company to new heights.
In this regard, Jiankangyuan stated that it will continue to implement the dual-drive strategy of innovative drugs and high-barrier complex preparations, increase innovation efforts, improve evidence-based medical research, and maintain the subsequent life cycle of products; at the same time, it will explore new technological models and integrate digital transformation into all aspects of the industrial chain. In addition, the company will continue to sink into grassroots hospitals, do a good job in product popularization, so that more patients can use better domestic innovative drugs, and adhere to the mission and vision of "For health, for tomorrow" and "Making good medicine with care".
With the comprehensive strengthening of intellectual property protection in China, and the accelerated realization of the benefits of intellectual property utilization, , Jiankangyuan is expected to in a market with continuously improved intellectual property protection, relying on its own resource integration and scientific research achievement transformation capabilities, accelerate its transformation into an innovative and comprehensive pharmaceutical enterprise that promotes high-quality development of the industry.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home